Chandel Abhimanyu, Leazer Sahar, Alcover Karl C, Farley Josiah, Berk Joshua, Jayne Christopher, Mcnutt Ryan, Olsen Meredith, Allard Rhonda, Yang Jiahong, Johnson Caitlyn, Tripathi Ananya, Rechtin Maria, Leon Mathew, Williams Mathias, Sheth Phorum, Messer Kyle, Chung Kevin K, Collen Jacob
Department of Pulmonary and Critical Care Medicine, Walter Reed National Medical Center, Bethesda, MD.
Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD.
Crit Care Explor. 2023 Mar 3;5(3):e0876. doi: 10.1097/CCE.0000000000000876. eCollection 2023 Mar.
To perform a systematic review and meta-analysis to generate estimates of mortality in patients with COVID-19 that required hospitalization, ICU admission, and organ support.
A systematic search of PubMed, Embase, and the Cochrane databases was conducted up to December 31, 2021.
Previously peer-reviewed observational studies that reported ICU, mechanical ventilation (MV), renal replacement therapy (RRT) or extracorporeal membrane oxygenation (ECMO)-related mortality among greater than or equal to 100 individual patients.
Random-effects meta-analysis was used to generate pooled estimates of case fatality rates (CFRs) for in-hospital, ICU, MV, RRT, and ECMO-related mortality. ICU-related mortality was additionally analyzed by the study country of origin. Sensitivity analyses of CFR were assessed based on completeness of follow-up data, by year, and when only studies judged to be of high quality were included.
One hundred fifty-seven studies evaluating 948,309 patients were included. The CFR for in-hospital mortality, ICU mortality, MV, RRT, and ECMO were 25.9% (95% CI: 24.0-27.8%), 37.3% (95% CI: 34.6-40.1%), 51.6% (95% CI: 46.1-57.0%), 66.1% (95% CI: 59.7-72.2%), and 58.0% (95% CI: 46.9-68.9%), respectively. MV (52.7%, 95% CI: 47.5-58.0% vs 31.3%, 95% CI: 16.1-48.9%; = 0.023) and RRT-related mortality (66.7%, 95% CI: 60.1-73.0% vs 50.3%, 95% CI: 42.4-58.2%; = 0.003) decreased from 2020 to 2021.
We present updated estimates of CFR for patients hospitalized and requiring intensive care for the management of COVID-19. Although mortality remain high and varies considerably worldwide, we found the CFR in patients supported with MV significantly improved since 2020.
进行一项系统评价和荟萃分析,以得出需要住院、入住重症监护病房(ICU)及接受器官支持的新型冠状病毒肺炎(COVID-19)患者的死亡率估计值。
截至2021年12月31日,对PubMed、Embase和Cochrane数据库进行了系统检索。
既往经过同行评审的观察性研究,报告了100例及以上个体患者中与ICU、机械通气(MV)、肾脏替代治疗(RRT)或体外膜肺氧合(ECMO)相关的死亡率。
采用随机效应荟萃分析得出住院、ICU、MV、RRT及ECMO相关死亡率的合并病死率(CFR)估计值。还按研究的原产国对ICU相关死亡率进行了分析。基于随访数据的完整性、年份以及仅纳入判定为高质量的研究时,对CFR进行了敏感性分析。
纳入了157项评估948,309例患者的研究。住院死亡率、ICU死亡率、MV、RRT及ECMO的CFR分别为25.9%(95%置信区间:24.0% - 27.8%)、37.3%(95%置信区间:34.6% - 40.1%)、51.6%(95%置信区间:46.1% - 57.0%)、66.1%(95%置信区间:59.7% - 72.2%)和58.0%(95%置信区间:46.9% - 68.9%)。MV(52.7%,95%置信区间:47.5% - 58.0%对比31.3%,95%置信区间:16.1% - 48.9%;P = 0.023)和RRT相关死亡率(66.7%,95%置信区间:60.1% - 73.0%对比50.3%,95%置信区间:42.4% - 58.2%;P = 0.003)从2020年到2021年有所下降。
我们给出了因COVID-19住院并需要重症监护患者的CFR最新估计值。尽管死亡率仍然很高且在全球范围内差异很大,但我们发现自2020年以来接受MV支持的患者的CFR有显著改善。